Short answer
Replimune Group, Inc. (REPL) filed its Q4 2025 10-Q quarterly report on Feb 3, 2026 for the quarter ended Dec 31, 2025.
Q4 2025 key financials · XBRL
- Net income
- −$71M
- −6.9% YoY · +14.6% QoQ
- EPS (diluted)
- −$0.77
- +3.8% YoY · +14.4% QoQ
Source: XBRL data from the Replimune Group, Inc. (REPL) Q4 2025 10-Q on SEC EDGAR. USD.
Replimune Group, Inc. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Regulatory risk: FDA issued a CRL for RP1 plus nivolumab BLA in July 2025
- Regulatory risk: FDA accepted the resubmitted RP1 BLA in October 2025 without assurance of approval
- Financial risk: Continued net losses and potential need for additional financing to achieve development goals
- Operational risk: Reliance on BMS, Regeneron, and Roche for checkpoint-blockade drug supplies
- Market risk: Tariffs on pharmaceuticals and ingredients could increase manufacturing and development costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Replimune Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.